RxSight investors with losses over $75,000 may sue for damages.

Faruqi & Faruqi, a securities law firm, is investigating potential claims against RxSight, Inc. for alleged misrepresentations in the company's financial statements between May 7, 2024 and July 8, 2025. The firm encourages investors who suffered losses exceeding $75,000 to contact Josh Wilson directly to discuss their options. A federal securities class action has been filed against the company, with a September 22, 2025 deadline to seek the role of lead plaintiff.

New York, Sept. 12, 2025 — Leading securities law firm Faruqi & Faruqi, LLP has announced that it is investigating potential claims against RxSight, Inc. (NASDAQ: RXST) for alleged misrepresentations in the company's financial statements between May 7, 2024 and July 8, 2025. The firm encourages investors who suffered losses exceeding $75,000 to contact Josh Wilson directly to discuss their options. A federal securities class action has been filed against the company, with a September 22, 2025 deadline to seek the role of lead plaintiff Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight^[1].

The complaint alleges that RxSight and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose significant issues. These include adoption challenges and structural problems that led to declines in sales and utilization, overstated demand for the company's products, and an inability to meet previously issued financial guidance for fiscal year 2025 Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight^[1].

On July 8, 2025, after the market closed, RxSight reported significant declines in Light Adjustable Lens (LAL) sales, LAL utilization, and overall revenue. The company also lowered its full-year 2025 guidance by approximately $42.5 million at the midpoint. The stock price subsequently fell by $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025 Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight^[1].

Investors are reminded that they have until September 22, 2025 to ask the Court to be appointed as lead plaintiff in the case. The lead plaintiff will oversee the litigation on behalf of the class, and any member of the class can choose to remain an absent class member Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight^[1].

Faruqi & Faruqi, LLP encourages anyone with information regarding RxSight's conduct to contact the firm, including whistleblowers, former employees, and shareholders. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995 Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight^[1].

For more information, investors can visit www.faruqilaw.com/RXST or contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight^[1].